[China BD 2023] Highlightll and Biohaven enters a 970 million USD License on Dual TYK2/JAK1 Inhibitor TLL-041 (BHV-8000)

Announced Date: 2023-03-22 March 22, 2023)

Asset Name: TLL-041 (BHV-8000)

Licensor (Seller): Hangzhou Highlightll Pharmaceutica (China)

Licensee (Buyer): Biohaven Therapeutics (US)

.

Asset Modality: Small Molecule

Asset Target: Dual TYK2/JAK1 Inhibitor 

Potential Indication: brain disorders

Current until deal:  phase I

.

Scope of Authority:

Biohaven acquired global rights, excluding China regions, for the development of an oral, brain-penetrant, dual inhibitor of Tyrosine Kinase 2 (TYK2) and Janus Kinase 1 (JAK1) BHV-8000 (previously TLL-041) for the treatment of brain disorders.

Biohaven and Highlightll will coordinate clinical development across global regions.

.

Payment Detail:

Highlightll will receive 

$10 million in upfront cash and $10 million in BHVN equity,

Development and commercial milestone payments of up to $950 million.

Tiered royalty payments ranging from mid-single digit to lower teens percentages.  

.

Link:

Biohaven Acquires Exclusive License for Oral, Brain-Penetrant, Dual TYK2/JAK1 Inhibitor for Immune-Mediated Brain Disorders | Biohaven, Ltd.

.

Note:

Chinese Name of Hangzhou Highlightll Pharmaceutical, 杭州高光制药